nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—kidney cancer	0.265	1	CbGaD
Dihydroergotamine—HTR2B—Sorafenib—kidney cancer	0.0864	0.165	CbGbCtD
Dihydroergotamine—ABCB1—Temsirolimus—kidney cancer	0.0587	0.112	CbGbCtD
Dihydroergotamine—CYP3A4—Everolimus—kidney cancer	0.0521	0.0992	CbGbCtD
Dihydroergotamine—CYP3A4—Temsirolimus—kidney cancer	0.0352	0.067	CbGbCtD
Dihydroergotamine—ABCB1—Pazopanib—kidney cancer	0.0308	0.0588	CbGbCtD
Dihydroergotamine—ABCB1—Dactinomycin—kidney cancer	0.0282	0.0538	CbGbCtD
Dihydroergotamine—ABCB1—Gemcitabine—kidney cancer	0.0223	0.0425	CbGbCtD
Dihydroergotamine—ABCB1—Erlotinib—kidney cancer	0.022	0.0419	CbGbCtD
Dihydroergotamine—ABCB1—Paclitaxel—kidney cancer	0.0201	0.0384	CbGbCtD
Dihydroergotamine—CYP3A4—Pazopanib—kidney cancer	0.0185	0.0352	CbGbCtD
Dihydroergotamine—ABCB1—Sorafenib—kidney cancer	0.0179	0.0341	CbGbCtD
Dihydroergotamine—ABCB1—Vinblastine—kidney cancer	0.0177	0.0337	CbGbCtD
Dihydroergotamine—ABCB1—Vincristine—kidney cancer	0.0174	0.0331	CbGbCtD
Dihydroergotamine—ABCB1—Sunitinib—kidney cancer	0.0145	0.0276	CbGbCtD
Dihydroergotamine—CYP3A4—Erlotinib—kidney cancer	0.0132	0.0251	CbGbCtD
Dihydroergotamine—CYP3A4—Paclitaxel—kidney cancer	0.0121	0.023	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—kidney cancer	0.0109	0.0207	CbGbCtD
Dihydroergotamine—CYP3A4—Sorafenib—kidney cancer	0.0107	0.0204	CbGbCtD
Dihydroergotamine—CYP3A4—Vinblastine—kidney cancer	0.0106	0.0202	CbGbCtD
Dihydroergotamine—CYP3A4—Vincristine—kidney cancer	0.0104	0.0198	CbGbCtD
Dihydroergotamine—CYP3A4—Sunitinib—kidney cancer	0.00868	0.0166	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—kidney cancer	0.0065	0.0124	CbGbCtD
Dihydroergotamine—Eye pain—Doxorubicin—kidney cancer	0.000224	0.00106	CcSEcCtD
Dihydroergotamine—Nervousness—Paclitaxel—kidney cancer	0.000223	0.00106	CcSEcCtD
Dihydroergotamine—Dizziness—Vinblastine—kidney cancer	0.000222	0.00106	CcSEcCtD
Dihydroergotamine—Dizziness—Everolimus—kidney cancer	0.000221	0.00105	CcSEcCtD
Dihydroergotamine—Muscle spasms—Paclitaxel—kidney cancer	0.000221	0.00105	CcSEcCtD
Dihydroergotamine—Body temperature increased—Sunitinib—kidney cancer	0.000221	0.00105	CcSEcCtD
Dihydroergotamine—Abdominal pain—Sunitinib—kidney cancer	0.000221	0.00105	CcSEcCtD
Dihydroergotamine—Diarrhoea—Erlotinib—kidney cancer	0.000221	0.00105	CcSEcCtD
Dihydroergotamine—Hypotension—Vincristine—kidney cancer	0.000221	0.00105	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Dactinomycin—kidney cancer	0.000218	0.00104	CcSEcCtD
Dihydroergotamine—Rhinitis—Capecitabine—kidney cancer	0.000217	0.00103	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000217	0.00103	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000216	0.00103	CcSEcCtD
Dihydroergotamine—Hot flush—Doxorubicin—kidney cancer	0.000216	0.00103	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Capecitabine—kidney cancer	0.000216	0.00103	CcSEcCtD
Dihydroergotamine—Tremor—Paclitaxel—kidney cancer	0.000215	0.00102	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000215	0.00102	CcSEcCtD
Dihydroergotamine—Pharyngitis—Capecitabine—kidney cancer	0.000215	0.00102	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—kidney cancer	0.000214	0.00102	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Sorafenib—kidney cancer	0.000214	0.00102	CcSEcCtD
Dihydroergotamine—Insomnia—Vincristine—kidney cancer	0.000214	0.00102	CcSEcCtD
Dihydroergotamine—Anorexia—Gemcitabine—kidney cancer	0.000214	0.00102	CcSEcCtD
Dihydroergotamine—Vomiting—Vinblastine—kidney cancer	0.000213	0.00102	CcSEcCtD
Dihydroergotamine—Dizziness—Erlotinib—kidney cancer	0.000213	0.00101	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Paclitaxel—kidney cancer	0.000213	0.00101	CcSEcCtD
Dihydroergotamine—Vomiting—Everolimus—kidney cancer	0.000213	0.00101	CcSEcCtD
Dihydroergotamine—Paraesthesia—Vincristine—kidney cancer	0.000212	0.00101	CcSEcCtD
Dihydroergotamine—Agitation—Paclitaxel—kidney cancer	0.000211	0.00101	CcSEcCtD
Dihydroergotamine—Rash—Everolimus—kidney cancer	0.000211	0.001	CcSEcCtD
Dihydroergotamine—Dermatitis—Everolimus—kidney cancer	0.000211	0.001	CcSEcCtD
Dihydroergotamine—Headache—Vinblastine—kidney cancer	0.00021	0.001	CcSEcCtD
Dihydroergotamine—Headache—Everolimus—kidney cancer	0.000209	0.000996	CcSEcCtD
Dihydroergotamine—Hypotension—Gemcitabine—kidney cancer	0.000209	0.000996	CcSEcCtD
Dihydroergotamine—Abdominal pain—Dactinomycin—kidney cancer	0.000209	0.000994	CcSEcCtD
Dihydroergotamine—Body temperature increased—Dactinomycin—kidney cancer	0.000209	0.000994	CcSEcCtD
Dihydroergotamine—Visual impairment—Capecitabine—kidney cancer	0.000209	0.000994	CcSEcCtD
Dihydroergotamine—Asthenia—Sorafenib—kidney cancer	0.000208	0.000991	CcSEcCtD
Dihydroergotamine—Malaise—Paclitaxel—kidney cancer	0.000207	0.000986	CcSEcCtD
Dihydroergotamine—Vertigo—Paclitaxel—kidney cancer	0.000207	0.000983	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000206	0.00098	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Sunitinib—kidney cancer	0.000206	0.000979	CcSEcCtD
Dihydroergotamine—Decreased appetite—Vincristine—kidney cancer	0.000205	0.000977	CcSEcCtD
Dihydroergotamine—Pruritus—Sorafenib—kidney cancer	0.000205	0.000977	CcSEcCtD
Dihydroergotamine—Vomiting—Erlotinib—kidney cancer	0.000205	0.000976	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000204	0.000971	CcSEcCtD
Dihydroergotamine—Fatigue—Vincristine—kidney cancer	0.000204	0.000969	CcSEcCtD
Dihydroergotamine—Rash—Erlotinib—kidney cancer	0.000203	0.000968	CcSEcCtD
Dihydroergotamine—Dermatitis—Erlotinib—kidney cancer	0.000203	0.000967	CcSEcCtD
Dihydroergotamine—Palpitations—Paclitaxel—kidney cancer	0.000203	0.000966	CcSEcCtD
Dihydroergotamine—Insomnia—Gemcitabine—kidney cancer	0.000203	0.000964	CcSEcCtD
Dihydroergotamine—Headache—Erlotinib—kidney cancer	0.000202	0.000961	CcSEcCtD
Dihydroergotamine—Tinnitus—Capecitabine—kidney cancer	0.000202	0.000961	CcSEcCtD
Dihydroergotamine—Pain—Vincristine—kidney cancer	0.000202	0.000961	CcSEcCtD
Dihydroergotamine—Paraesthesia—Gemcitabine—kidney cancer	0.000201	0.000957	CcSEcCtD
Dihydroergotamine—Flushing—Capecitabine—kidney cancer	0.000201	0.000957	CcSEcCtD
Dihydroergotamine—Asthenia—Sunitinib—kidney cancer	0.0002	0.000953	CcSEcCtD
Dihydroergotamine—Dyspnoea—Gemcitabine—kidney cancer	0.0002	0.00095	CcSEcCtD
Dihydroergotamine—Nausea—Vinblastine—kidney cancer	0.000199	0.000948	CcSEcCtD
Dihydroergotamine—Somnolence—Gemcitabine—kidney cancer	0.000199	0.000948	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—kidney cancer	0.000199	0.000946	CcSEcCtD
Dihydroergotamine—Nausea—Everolimus—kidney cancer	0.000199	0.000945	CcSEcCtD
Dihydroergotamine—Diarrhoea—Sorafenib—kidney cancer	0.000199	0.000945	CcSEcCtD
Dihydroergotamine—Hypertension—Paclitaxel—kidney cancer	0.000199	0.000944	CcSEcCtD
Dihydroergotamine—Pruritus—Sunitinib—kidney cancer	0.000198	0.00094	CcSEcCtD
Dihydroergotamine—Myalgia—Paclitaxel—kidney cancer	0.000196	0.000931	CcSEcCtD
Dihydroergotamine—Arthralgia—Paclitaxel—kidney cancer	0.000196	0.000931	CcSEcCtD
Dihydroergotamine—Anxiety—Paclitaxel—kidney cancer	0.000195	0.000928	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—kidney cancer	0.000195	0.000927	CcSEcCtD
Dihydroergotamine—Decreased appetite—Gemcitabine—kidney cancer	0.000195	0.000927	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Dactinomycin—kidney cancer	0.000195	0.000927	CcSEcCtD
Dihydroergotamine—Chills—Capecitabine—kidney cancer	0.000194	0.000925	CcSEcCtD
Dihydroergotamine—Discomfort—Paclitaxel—kidney cancer	0.000193	0.00092	CcSEcCtD
Dihydroergotamine—Fatigue—Gemcitabine—kidney cancer	0.000193	0.000919	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Vincristine—kidney cancer	0.000193	0.000919	CcSEcCtD
Dihydroergotamine—Dizziness—Sorafenib—kidney cancer	0.000192	0.000913	CcSEcCtD
Dihydroergotamine—Pain—Gemcitabine—kidney cancer	0.000192	0.000912	CcSEcCtD
Dihydroergotamine—Nausea—Erlotinib—kidney cancer	0.000192	0.000912	CcSEcCtD
Dihydroergotamine—Dry mouth—Paclitaxel—kidney cancer	0.000191	0.000911	CcSEcCtD
Dihydroergotamine—Diarrhoea—Sunitinib—kidney cancer	0.000191	0.000909	CcSEcCtD
Dihydroergotamine—Asthenia—Dactinomycin—kidney cancer	0.00019	0.000902	CcSEcCtD
Dihydroergotamine—Confusional state—Paclitaxel—kidney cancer	0.000189	0.0009	CcSEcCtD
Dihydroergotamine—Oedema—Paclitaxel—kidney cancer	0.000188	0.000893	CcSEcCtD
Dihydroergotamine—Abdominal pain—Vincristine—kidney cancer	0.000187	0.000888	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vincristine—kidney cancer	0.000187	0.000888	CcSEcCtD
Dihydroergotamine—Dizziness—Sunitinib—kidney cancer	0.000185	0.000879	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Gemcitabine—kidney cancer	0.000185	0.000878	CcSEcCtD
Dihydroergotamine—Shock—Paclitaxel—kidney cancer	0.000185	0.000878	CcSEcCtD
Dihydroergotamine—Vomiting—Sorafenib—kidney cancer	0.000185	0.000878	CcSEcCtD
Dihydroergotamine—Tachycardia—Paclitaxel—kidney cancer	0.000183	0.000871	CcSEcCtD
Dihydroergotamine—Rash—Sorafenib—kidney cancer	0.000183	0.000871	CcSEcCtD
Dihydroergotamine—Dermatitis—Sorafenib—kidney cancer	0.000183	0.00087	CcSEcCtD
Dihydroergotamine—Headache—Sorafenib—kidney cancer	0.000182	0.000865	CcSEcCtD
Dihydroergotamine—Muscle spasms—Capecitabine—kidney cancer	0.000181	0.000863	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000181	0.000863	CcSEcCtD
Dihydroergotamine—Diarrhoea—Dactinomycin—kidney cancer	0.000181	0.000861	CcSEcCtD
Dihydroergotamine—Anorexia—Paclitaxel—kidney cancer	0.000179	0.000851	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—kidney cancer	0.000178	0.000847	CcSEcCtD
Dihydroergotamine—Vomiting—Sunitinib—kidney cancer	0.000178	0.000845	CcSEcCtD
Dihydroergotamine—Body temperature increased—Gemcitabine—kidney cancer	0.000177	0.000843	CcSEcCtD
Dihydroergotamine—Tremor—Capecitabine—kidney cancer	0.000177	0.000841	CcSEcCtD
Dihydroergotamine—Rash—Sunitinib—kidney cancer	0.000176	0.000838	CcSEcCtD
Dihydroergotamine—Dermatitis—Sunitinib—kidney cancer	0.000176	0.000837	CcSEcCtD
Dihydroergotamine—Hypotension—Paclitaxel—kidney cancer	0.000175	0.000834	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Capecitabine—kidney cancer	0.000175	0.000833	CcSEcCtD
Dihydroergotamine—Headache—Sunitinib—kidney cancer	0.000175	0.000832	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—kidney cancer	0.000175	0.00083	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Vincristine—kidney cancer	0.000174	0.000828	CcSEcCtD
Dihydroergotamine—Nausea—Sorafenib—kidney cancer	0.000172	0.00082	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000171	0.000813	CcSEcCtD
Dihydroergotamine—Malaise—Capecitabine—kidney cancer	0.00017	0.000809	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—kidney cancer	0.00017	0.000809	CcSEcCtD
Dihydroergotamine—Insomnia—Paclitaxel—kidney cancer	0.00017	0.000807	CcSEcCtD
Dihydroergotamine—Vertigo—Capecitabine—kidney cancer	0.00017	0.000806	CcSEcCtD
Dihydroergotamine—Asthenia—Vincristine—kidney cancer	0.00017	0.000806	CcSEcCtD
Dihydroergotamine—Paraesthesia—Paclitaxel—kidney cancer	0.000168	0.000801	CcSEcCtD
Dihydroergotamine—Vomiting—Dactinomycin—kidney cancer	0.000168	0.0008	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—kidney cancer	0.000168	0.000798	CcSEcCtD
Dihydroergotamine—Dyspnoea—Paclitaxel—kidney cancer	0.000167	0.000796	CcSEcCtD
Dihydroergotamine—Somnolence—Paclitaxel—kidney cancer	0.000167	0.000793	CcSEcCtD
Dihydroergotamine—Palpitations—Capecitabine—kidney cancer	0.000167	0.000793	CcSEcCtD
Dihydroergotamine—Rash—Dactinomycin—kidney cancer	0.000167	0.000793	CcSEcCtD
Dihydroergotamine—Nausea—Sunitinib—kidney cancer	0.000166	0.000789	CcSEcCtD
Dihydroergotamine—Dyspepsia—Paclitaxel—kidney cancer	0.000165	0.000786	CcSEcCtD
Dihydroergotamine—Decreased appetite—Paclitaxel—kidney cancer	0.000163	0.000776	CcSEcCtD
Dihydroergotamine—Hypertension—Capecitabine—kidney cancer	0.000163	0.000775	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000162	0.000772	CcSEcCtD
Dihydroergotamine—Fatigue—Paclitaxel—kidney cancer	0.000162	0.00077	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vincristine—kidney cancer	0.000162	0.000769	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—kidney cancer	0.000161	0.000767	CcSEcCtD
Dihydroergotamine—Asthenia—Gemcitabine—kidney cancer	0.000161	0.000765	CcSEcCtD
Dihydroergotamine—Arthralgia—Capecitabine—kidney cancer	0.000161	0.000764	CcSEcCtD
Dihydroergotamine—Myalgia—Capecitabine—kidney cancer	0.000161	0.000764	CcSEcCtD
Dihydroergotamine—Pain—Paclitaxel—kidney cancer	0.00016	0.000763	CcSEcCtD
Dihydroergotamine—Anxiety—Capecitabine—kidney cancer	0.00016	0.000761	CcSEcCtD
Dihydroergotamine—Discomfort—Capecitabine—kidney cancer	0.000159	0.000755	CcSEcCtD
Dihydroergotamine—Pruritus—Gemcitabine—kidney cancer	0.000159	0.000754	CcSEcCtD
Dihydroergotamine—Dry mouth—Capecitabine—kidney cancer	0.000157	0.000747	CcSEcCtD
Dihydroergotamine—Nausea—Dactinomycin—kidney cancer	0.000157	0.000747	CcSEcCtD
Dihydroergotamine—Dizziness—Vincristine—kidney cancer	0.000156	0.000743	CcSEcCtD
Dihydroergotamine—Confusional state—Capecitabine—kidney cancer	0.000155	0.000739	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Paclitaxel—kidney cancer	0.000155	0.000736	CcSEcCtD
Dihydroergotamine—Oedema—Capecitabine—kidney cancer	0.000154	0.000732	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000153	0.00073	CcSEcCtD
Dihydroergotamine—Diarrhoea—Gemcitabine—kidney cancer	0.000153	0.000729	CcSEcCtD
Dihydroergotamine—Shock—Capecitabine—kidney cancer	0.000152	0.000721	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—kidney cancer	0.000151	0.00072	CcSEcCtD
Dihydroergotamine—Tachycardia—Capecitabine—kidney cancer	0.00015	0.000715	CcSEcCtD
Dihydroergotamine—Vomiting—Vincristine—kidney cancer	0.00015	0.000714	CcSEcCtD
Dihydroergotamine—Urticaria—Paclitaxel—kidney cancer	0.000149	0.000709	CcSEcCtD
Dihydroergotamine—Rash—Vincristine—kidney cancer	0.000149	0.000709	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Capecitabine—kidney cancer	0.000149	0.000708	CcSEcCtD
Dihydroergotamine—Dermatitis—Vincristine—kidney cancer	0.000149	0.000708	CcSEcCtD
Dihydroergotamine—Abdominal pain—Paclitaxel—kidney cancer	0.000148	0.000706	CcSEcCtD
Dihydroergotamine—Body temperature increased—Paclitaxel—kidney cancer	0.000148	0.000706	CcSEcCtD
Dihydroergotamine—Headache—Vincristine—kidney cancer	0.000148	0.000704	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—kidney cancer	0.000147	0.000698	CcSEcCtD
Dihydroergotamine—Anorexia—Capecitabine—kidney cancer	0.000147	0.000698	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—kidney cancer	0.000146	0.000695	CcSEcCtD
Dihydroergotamine—Hypotension—Capecitabine—kidney cancer	0.000144	0.000684	CcSEcCtD
Dihydroergotamine—Vomiting—Gemcitabine—kidney cancer	0.000143	0.000678	CcSEcCtD
Dihydroergotamine—Rash—Gemcitabine—kidney cancer	0.000141	0.000672	CcSEcCtD
Dihydroergotamine—Dermatitis—Gemcitabine—kidney cancer	0.000141	0.000672	CcSEcCtD
Dihydroergotamine—Headache—Gemcitabine—kidney cancer	0.00014	0.000668	CcSEcCtD
Dihydroergotamine—Nausea—Vincristine—kidney cancer	0.00014	0.000667	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00014	0.000667	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—kidney cancer	0.00014	0.000666	CcSEcCtD
Dihydroergotamine—Insomnia—Capecitabine—kidney cancer	0.000139	0.000662	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000139	0.000661	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—kidney cancer	0.000139	0.00066	CcSEcCtD
Dihydroergotamine—Paraesthesia—Capecitabine—kidney cancer	0.000138	0.000658	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Paclitaxel—kidney cancer	0.000138	0.000658	CcSEcCtD
Dihydroergotamine—Dyspnoea—Capecitabine—kidney cancer	0.000137	0.000653	CcSEcCtD
Dihydroergotamine—Dyspepsia—Capecitabine—kidney cancer	0.000136	0.000645	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—kidney cancer	0.000135	0.00064	CcSEcCtD
Dihydroergotamine—Asthenia—Paclitaxel—kidney cancer	0.000135	0.00064	CcSEcCtD
Dihydroergotamine—Decreased appetite—Capecitabine—kidney cancer	0.000134	0.000637	CcSEcCtD
Dihydroergotamine—Nausea—Gemcitabine—kidney cancer	0.000133	0.000633	CcSEcCtD
Dihydroergotamine—Fatigue—Capecitabine—kidney cancer	0.000133	0.000631	CcSEcCtD
Dihydroergotamine—Pruritus—Paclitaxel—kidney cancer	0.000133	0.000631	CcSEcCtD
Dihydroergotamine—Pain—Capecitabine—kidney cancer	0.000132	0.000626	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—kidney cancer	0.00013	0.00062	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—kidney cancer	0.00013	0.000617	CcSEcCtD
Dihydroergotamine—Diarrhoea—Paclitaxel—kidney cancer	0.000128	0.000611	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Capecitabine—kidney cancer	0.000127	0.000604	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000126	0.000599	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—kidney cancer	0.000125	0.000596	CcSEcCtD
Dihydroergotamine—Dizziness—Paclitaxel—kidney cancer	0.000124	0.00059	CcSEcCtD
Dihydroergotamine—Urticaria—Capecitabine—kidney cancer	0.000122	0.000582	CcSEcCtD
Dihydroergotamine—Abdominal pain—Capecitabine—kidney cancer	0.000122	0.000579	CcSEcCtD
Dihydroergotamine—Body temperature increased—Capecitabine—kidney cancer	0.000122	0.000579	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—kidney cancer	0.000119	0.000568	CcSEcCtD
Dihydroergotamine—Vomiting—Paclitaxel—kidney cancer	0.000119	0.000567	CcSEcCtD
Dihydroergotamine—Rash—Paclitaxel—kidney cancer	0.000118	0.000563	CcSEcCtD
Dihydroergotamine—Dermatitis—Paclitaxel—kidney cancer	0.000118	0.000562	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—kidney cancer	0.000118	0.000562	CcSEcCtD
Dihydroergotamine—Headache—Paclitaxel—kidney cancer	0.000118	0.000559	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—kidney cancer	0.000117	0.000556	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Capecitabine—kidney cancer	0.000113	0.00054	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—kidney cancer	0.000113	0.000537	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—kidney cancer	0.000112	0.000532	CcSEcCtD
Dihydroergotamine—Nausea—Paclitaxel—kidney cancer	0.000111	0.00053	CcSEcCtD
Dihydroergotamine—Asthenia—Capecitabine—kidney cancer	0.00011	0.000526	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—kidney cancer	0.00011	0.000522	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—kidney cancer	0.000109	0.00052	CcSEcCtD
Dihydroergotamine—Pruritus—Capecitabine—kidney cancer	0.000109	0.000518	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—kidney cancer	0.000107	0.000511	CcSEcCtD
Dihydroergotamine—Diarrhoea—Capecitabine—kidney cancer	0.000105	0.000501	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—kidney cancer	0.000105	0.000499	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—kidney cancer	0.000104	0.000493	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—kidney cancer	0.000104	0.000493	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—kidney cancer	0.000103	0.000491	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—kidney cancer	0.000102	0.000487	CcSEcCtD
Dihydroergotamine—Dizziness—Capecitabine—kidney cancer	0.000102	0.000484	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—kidney cancer	0.000101	0.000482	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—kidney cancer	0.0001	0.000476	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—kidney cancer	9.93e-05	0.000472	CcSEcCtD
Dihydroergotamine—Vomiting—Capecitabine—kidney cancer	9.79e-05	0.000466	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—kidney cancer	9.77e-05	0.000465	CcSEcCtD
Dihydroergotamine—Rash—Capecitabine—kidney cancer	9.71e-05	0.000462	CcSEcCtD
Dihydroergotamine—Dermatitis—Capecitabine—kidney cancer	9.7e-05	0.000461	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—kidney cancer	9.69e-05	0.000461	CcSEcCtD
Dihydroergotamine—Headache—Capecitabine—kidney cancer	9.65e-05	0.000459	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—kidney cancer	9.6e-05	0.000456	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—kidney cancer	9.46e-05	0.00045	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—kidney cancer	9.28e-05	0.000441	CcSEcCtD
Dihydroergotamine—Nausea—Capecitabine—kidney cancer	9.15e-05	0.000435	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	9.04e-05	0.00043	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—kidney cancer	8.98e-05	0.000427	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—kidney cancer	8.91e-05	0.000424	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—kidney cancer	8.85e-05	0.000421	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—kidney cancer	8.82e-05	0.00042	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—kidney cancer	8.74e-05	0.000416	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—kidney cancer	8.63e-05	0.00041	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—kidney cancer	8.56e-05	0.000407	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—kidney cancer	8.49e-05	0.000404	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—kidney cancer	8.18e-05	0.000389	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—kidney cancer	8.12e-05	0.000386	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—kidney cancer	7.89e-05	0.000375	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—kidney cancer	7.85e-05	0.000373	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—kidney cancer	7.85e-05	0.000373	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—kidney cancer	7.31e-05	0.000348	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—kidney cancer	7.12e-05	0.000339	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—kidney cancer	7.02e-05	0.000334	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—kidney cancer	6.79e-05	0.000323	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—kidney cancer	6.56e-05	0.000312	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—kidney cancer	6.31e-05	0.0003	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—kidney cancer	6.26e-05	0.000298	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—kidney cancer	6.25e-05	0.000297	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—kidney cancer	6.22e-05	0.000296	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—kidney cancer	5.9e-05	0.00028	CcSEcCtD
